Navigation Links
SyntheMed Announces New Management Appointments
Date:10/2/2008

ISELIN, N.J., Oct. 2 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that Richard L. Franklin, MD, the company's Chairman, has assumed the newly-created position of Executive Chairman and Gere S. diZerega, MD, one of the company's clinical advisors, has assumed the newly-created position of Medical Director. In these consultancy roles, Dr. Franklin will be primarily involved with strategic planning, external communications and Board leadership whereas Dr. diZerega will focus on clinical and regulatory strategy and product planning. Robert P. Hickey, the company's President & CEO stated, "We are very fortunate that Rick and Gere have agreed to expand their involvement with our company and we look forward to benefiting from their experience and expertise."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products lead by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Completes $4.0 Million Equity Placement
2. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
3. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
4. SyntheMed Files Universal Shelf Registration
5. SyntheMed to Present at the Acumen BioFin Conference
6. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
7. Alba Therapeutics Corporation Announces Promotions
8. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
9. 23andMe Announces Breast Cancer Initiative
10. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 31, 2015. --> --> ... loss of $29.3 million, or $0.34 loss per share, compared to ... for the same period in 2014. For the year ended December ... or $1.05 loss per share, as compared to a net loss ...
(Date:2/11/2016)...  Spectra BioPharma Selling Solutions (Spectra) is a ... companies the experience, expertise, operational delivery and customer ... teams. Created in concert with industry leading commercial ... and tactical needs of its clients by providing ... personal and non-personal promotion. --> ...
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
Breaking Biology Technology:
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
Breaking Biology News(10 mins):